A combination of gene polymorphisms, JAK2, Calreticulin, and MPL driver mutations, and clinical parameters can predict the prognosis and clinical course (overt myelofibrosis or conversion to acute leukemia, thrombosis, and significant bleeding) [2,3,4]. The gene discussed is CALR; the disease is myelofibrosis.